BFS 주사기 시장 - 예측(2024-2029년)

The BFS syringe market was valued at US$406.801 million in 2022.

The healthcare and cosmetics industries' rising need for BFS syringes is anticipated to fuel market expansion. The market demand is being driven by the choice of modern pharmaceutical packaging types and unit dosage packaging. Pharmaceutical businesses utilize prefilled syringes with blow-fill seal (BFS) technology. Throughout the projection period, a considerable increase in the market for BFS syringes is anticipated as a result of this. Aseptic packaging companies are increasingly using the sterilizing technique known as blow-fill-seal (BFS) for packaging and automated processes. The BFS technology has received FDA (Food and Drug Administration) certification for use in the production of pharmaceutical and healthcare products employing an improved aseptic processing technique which has created favorable market dynamics for expansion of the BFS syringe market. The demand in the market is also anticipated to be fueled by the usage of these syringes for cosmetics items in serum applications and other skincare products.

Introduction:

To offer parental preparation with very little human involvement, BFS technology has recently received great application in the pharmaceutical business. Several regulating organizations, including the US Food and Drug Administration (FDA), view this technique as a preferable approach for aseptic filling of parental preparation. Pharmaceutical packaging companies take into account several benefits of BFS syringes, including their cheap operating costs, flexible package designs, high levels of sterility, low labour demand, and small component inventories. The technology was created in Europe, where it is in high demand, followed by North America. The method is commonly used in the pharmaceutical industry to fill the parental preparation with fairly little human interference. Additionally, it is used to fill eye drops, inhalation devices, intravenous fluids, and other parent preparations. The healthcare sector's emphasis on efficiency and dose precision has sparked advancements in syringe technology. The packaging and use of syringes are changing with the introduction of blow-fill-seal (BFS) syringes. Leading syringe producers are now progressively migrating to BFS technology, which is regarded as a superior technique for aseptically filling parental preparation by several regulatory organizations which has consequently positively influenced market growth.

Drivers:

• Rise in demand for aseptic packing is fueling market growth: With the introduction of automation in the packing business, BFS syringes provide a sterile solution and meet the demand for aseptic conditions. In terms of the number of clean items packed per minute, aseptic packaging using BFS syringe technology offers high precision which eventually fuels market growth.
• Growth of the pharma industry is propelling market demand: The exponential growth in the pharma sector is a prime reason for boosting market growth. Leading pharmaceutical producers utilize cutting-edge sterilizing processes to minimize operator interaction and the possibility of contamination while packing liquid pharmaceuticals. It is a desirable technique for medicine packaging because it provides flexible diversity in packaging design, cost-effectiveness, sterility, and low component inventory.
• BFS syringes reduce the chance of contamination hence creating market demand: Using automated BFS technology, syringes are manufactured, filled, and sealed all in one step. As a result, it reduces the chance of contamination and is therefore widely accepted among healthcare professionals.
• These syringes do not require refrigeration for their storage which consequently reduces prices: For the aseptic packing of respiratory, ophthalmic, oral, and pre-filled syringes, and injectable pharmaceuticals, a BFS syringe is often used. These products are handy for consumers and cost-effective for vendors because they don't require refrigeration and therefore are economical.
• Growing demand for vaccines from emerging economies: The surge in demand for vaccines from emerging economies is a major factor for market development. Syringe sales are expected to increase as immunization rates rise in nations like India. The main maker of syringes has also increased their production capacity as a result of the increasing demand for vaccinations.

Products offered by key companies:

• Prefilled ApiJect Injector, Apiject: Prefilled ApiJect Injector is offered by Apiject. It is a delivery device created to combine the advantages of prefilled syringes with the manufacturing effectiveness of multi-dose presentations.
• BD EffivaxTM Glass Prefillable Syringe, Becton, Dickinson and Company: BD, a prominent provider of medical technology unveiled a next-generation glass pre-fillable syringe (PFS) with new and stricter requirements for processability, cosmetics, contamination, and integrity. This PFS establishes a new benchmark in performance for vaccination PFS. To fulfil the complicated and changing demands of vaccine manufacture, the innovative BD EffivaxTM Glass Prefillable Syringe was created in partnership with top pharmaceutical firms.

The prominent growth in the Polypropylene sector under the material type segment

The pharmaceutical sector captured the major market share and is predicted to dominate the market over the forecast period. Leading pharmaceutical manufacturers prevent oversights and contamination by using cutting-edge sterilization technologies. Blow-fill-seal (BFS) technology provides safe and sterile packaging, making it a popular method for medicine packaging. Leading companies use these syringes utilizing the blow-fill-seal (BFS) technology in response to the growing need for aseptic packaging in the healthcare industry. Syringes are used in healthcare to lessen the danger of contamination and dose inaccuracy. Additionally, it eliminates the chance of reuse, preventing cross-infection which as a result is a major factor driving the market growth.

European region is expected to hold a significant share of the BFS syringe market:

The European market is poised to expand significantly over the projection period. Europe is a top-tier region concerning pharmaceutical producers. The market players located in the European market are extensively involved in the export of pharma products The European market is forecasted to sustain its position as a top market for BSF syringe manufacturers. Pharmaceutical packaging industry giants have established bases in the European market, and they have a preference for blow-fill-seal technology to sterilize injectables, which serves to emphasize this even more. European-based businesses have continued to prioritize injectable packaging, which is fueling the market's explosive expansion. The demand for sophisticated aseptic packaging, such as vials, bottles, ampoules, and pre-filled syringes, is driving an increase in the use of blow-fill-seal (BFS) technology in the pharmaceutical industry.

Key developments:

• A next-generation glass pre-fillable syringe (PFS) from BD, a well-known supplier of medical equipment, was introduced with new and tighter specifications for processability, cosmetics, contamination, and integrity in September 2022. This PFS sets a new standard for performance in the field of immunization PFS. In collaboration with leading pharmaceutical companies, the ground-breaking BD EffivaxTM Glass Prefillable Syringe was developed to meet the complex and ever-changing requirements of vaccine manufacturing.
• Becton, Dickinson, and Company declared their intention to invest in a new manufacturing facility in Spain in November 2021. The company may be able to increase its capacity for pre-fillable syringe production as a result of this action.

SEGMENTS:

BY CAPACITY

• 0.5-1 ml
• 1-3 ml
• Above 3 ml

BY MATERIAL

• Polypropylene (PP)
• Polyvinyl Chloride (PVC)
• Others

BY END-USER

• Pharmaceutical and Healthcare
• Personal Care and Cosmetics
• Others

BY GEOGRAPHY

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Italy
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Research Process

3. EXECUTIVE SUMMARY

• 3.1. Key Findings

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. BFS SYRINGE MARKET, BY CAPACITY

• 5.1. Introduction
• 5.2. 0.5-1 ml
• 5.3. 1-3 ml
• 5.4. Above 3 ml

6. BFS SYRINGE MARKET, BY MATERIAL

• 6.1. Introduction
• 6.2. Polypropylene (PP)
• 6.3. Polyvinyl Chloride (PVC)
• 6.4. Others

7. BFS SYRINGE MARKET, BY END-USERS

• 7.1. Introduction
• 7.2. Pharmaceutical and Healthcare
• 7.3. Personal Care and Cosmetics
• 7.4. Others

8. BFS SYRINGE MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Italy
  • 8.4.5. Spain
  • 8.4.6. Others
• 8.5. The Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Taiwan
  • 8.6.6. Thailand
  • 8.6.7. Indonesia
  • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

• 10.1. BREVETTI ANGELA S.r.l.
• 10.2. Recipharm AB
• 10.3. The Ritedose Corporation
• 10.4. Amanta Healthcare
• 10.5. ApiJect Systems, Corp.
• 10.6. SIFI S.p.A
• 10.7. LyondellBasell Industries Holdings B.V.

Not an exhaustive list